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Introduction
Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function for 3 months or more.1 CKD has a high and consistent global prevalence.2,3 It is estimated that the prevalence of CKD is between 11 to 13% with the majority CKD is in stage 3. Millions of people have died from its complications each year.2,3 It is also ranked as the 17th leading cause of global years of life lost, and the third largest increase of any major cause of death.4 Based on National Basic Health Research (Riset Kesehatan Dasar, Riskesdas) 2013, the prevalence of CKD in Indonesia has increased with age, with a peak in the age above 75 years old.5Generally, CKD stage 1 and 2 show no clinical signs and symptoms, although a decrease in GFR has occurred.6 In advanced stage of CKD, clinical signs and symptoms may appear as a 
manifestation of declined filtration function. This may also cause some complications.1,6 
One of its complications is a decrease in muscle mass that occurs along with advancing stage of CKD.6 Low muscle mass can occur due to metabolic acidosis, insulin resistance, 
inflammation, and increased glucocorticoid production and angiotensin II in CKD patients. These conditions can activate catabolic pathways such as Ubiquitin–Proteasome System (UPS), caspase-3, lysosomes, and myostatin in protein degradation.7,8 Decrease muscle mass and muscle streng this associated with high risk of heart failure, fractures, infections, frailty, and insulin resistance.9 The reduction in muscle mass shows a higher risk of death.10 Disability, morbidity and even mortality can occur as a manifestation of comorbid complications of low muscle mass and muscle strength.9 The Healthcare and Social Security Agency (Badan Penyelenggara 
Jaminan Sosial Kesehatan, BPJS) in Indonesia shows that CKD treatment costs is placed second for health funding after heart disease,1 therefore, from an economic and clinical 
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Abstract
Background: Low muscle mass is one of the complications of chronic kidney disease (CKD), that may occur due to the accumulation of uremic toxins and other mechanisms related to CKD. The aim of this study was to explore the difference of muscle mass among CKD patients stage 3 to stage 5.
Methods: A cross-sectional study was conducted with comparative analysis, using secondary data collected during the year 2017 by total sampling method. Subjects were patients aged over 18 years with CKD stage 3 to stage 5 from three hospitals in Bandung. Chronic Kidney Disease stages were determined based on Glomerular Filtration Rate. Muscle mass data was determined using Bioelectrical Impedance Analysis, collected from previous research. Data were analyzed usingone-way ANOVA or Kruskal-Wallis test.
Results: One hundred subjects consisting of 57 men and 43 women were included in in this study with the mean muscle mass was 26.29%±4.86, of whom 67% of the patients had low muscle mass. There was no difference between male (27.21%±3.82) and female (28.36%±4.67). The muscle mass among 
patients withCKD stage 3 to stage 5 showed no significant results (p>0.05).
Conclusions: There is no difference in muscle mass among CKD stage 3 to stage 5.
Keywords: Chronic kidney disease, glomerular filtration rate, muscle mass
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perspective, prevention on CKD progression is required for further complications.12Research on CKD and muscle atrophy has been widely carried out, however, no studies have discussed about differences in muscle mass for each stage of CKD. This study aimed to explore the muscle mass differences among CKD stages.
MethodsThe design of this study was a cross-sectional with comparative analysis, conducted from April to August 2018 using secondary data from previous studyin 2017. Data were collected from three hospitals in Bandung, that were in Dr. Hasan Sadikin General Hospital, Dustira Hospital, and Kidney Special Hospitals Ny. R.A. Habibie. This study had been approved by the Health Research Ethics Committee Universitas Padjajaran Bandung (No.294/UN6.KEP/EC/2018).In brief, data from all patients aged over 18 years with CKD stage 3 to stage 5 who had not undergone hemodialysis were collected. Data of patients with malignancy, infectious diseases, severe diseases or patients who routinely consumed antioxidants, and patients with incomplete data that did not include the variables sought including muscle mass and GFR, were excluded. The collected data were grouped according to the stages of CKD i.e. stage 3, stage 4, and stage 5, based on the GFR in accordance with KDIGO 2012 Clinical Practice Guidelines for Evaluation and Management of Chronic Kidney Disease.1Skeletal muscle mass were measured using Bioelectrical Impedance Analysis (BIA). Measurements of muscle mass were performed in various body regions, namely 
trunk, upper limb, lower limb, and the whole body. Muscle mass data were also grouped into 4 categories: low, normal, high, and very high,13 and compared between age group and gender. Muscle mass were expressed in terms ofa ratio between muscle mass and body weight.13One-way ANOVA statistical test was conducted to explore the differences in muscle mass among CKD stages when the data were normally distributed or otherwise Kruskal-Wallis statistic test when the data was not normally distributed. Furthermore, post-hoc analysis was performed to assess the comparison between groups. Hypothesis 
tests were considered significant if the value of p<0.05. Multiple linear regression analysis was also conducted to control confounding variables. Data analysis was conducted using IBM SPSS Statistics v.23.
ResultsIn total, 100 data of CKD patients that was met the criteria was collected. The characteristics of the CKD patients were grouped according to the stage of CKD (Table 1). Most of patients were found to be male; however, there was no 
significant correlation between gender and CKD stages (p=0.765). As for age, stage 4 CKD patients were found to be older compared to CKD stage 3, in which it had the lowest median 
age of 54 years, and there was a significant age difference among CKD stage 3-5 (p=0.002). 
Furthermore, no significant difference in BMI among CKD stage 3-5 (p=0.067).The muscle mass in patients with CKD stage 3 to stage 5 was presented in Table 2. Measurements of muscle mass were performed in various body regions. Overall, there was an increase in muscle mass with the stage of CKD, 
Table 1 The Characteristicsof Chronic Kidney Disease patients based on Stages
Chronic Kidney Disease
P ValueStage 3 
(n=21)
Stage 4 
(n=34)
Stage 5 
(n=45)Gender, n (%)     Male 11 (52.38) 21 (61.76) 25 (55.56) 0.765     Female 10 (47.62) 13 (38.24) 20 (44.44)Age (years), median (min-max) 54 (24-69) 65 (28-77) 59 (33-78) 0.002*BMI (kg/m2),median (min-max) 23.75 (17.65–37.99) 24.39 (18.75-36.36) 22.11 (10.54-35.39) 0.067Note: BMI= Body Mass Index
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although the difference was not significant, except in the upper limb as shown in Table 2. Interestingly, not only the whole body’smuscle 
mass in female showed a significant increase with the stages (p=0.046),but also in the upper limb’s muscle mass (p=0.027).The result of the multiple linear regression tests to control confounding variables was shown in Table 3. After the multivariate test was performed to control confounding variables (BMI and age), the result showed similar 
results; there was no significant difference in muscle mass among male subjects with CKD stage 3 to stage 5 (p=0.565 and p=0.422). 
Interestingly, there was a significant difference (p=0.032 and p=0.021)in female subjects. The 
classical assumption test showed that there was no multicolinearity and error distribution and this had not followed normal distribution pattern. Transformation of the dependent variable was needed, so the error distribution followed the normal distribution pattern.
DiscussionChronic kidney disease is predominantly in male, and in our study, aged above 50 years. It is more common in older age due to a decline in renal function with increasing age and due to the presence of various risk factors of CKD in older individuals such as diabetes and 
Table 2 Muscle Mass in Chronic Kidney Disease Stage 3–5 Based on Gender
Muscle mass (%) Chronic Kidney Disease P Value
Stage 3 Stage 4 Stage 5Whole body 26.29±4.86 27.21±3.82 28.3±4.67 0.188Male 28.5 (21.8–35.1) 28.3 (18.3–37.8) 29.5 (16.0–39.2) 0.598Female 23.19±2.82 25.25±2.99 26.99±4.67 0.046*Trunk 18.9 (13.6–30) 20.5 (12.5-33.6) 23.6 (10.8–34.4) 0.071Male 23.7 (13.6–30) 21.9 (17.2-33.6) 23.8 (17.9–34.4) 0.553Female 17.53±2.60 18.72±3.01 21.16±5.04 0.055Upper Limb 30.4 (20.5-39.9) 33.8 (13.5-41.3) 34.9(18.7–48.5) 0.037*Male 35.0 (21.0-39.9) 34.4 (19.9-41.3) 36.3(30.4–42.9) 0.591Female 25.66±3.96 27.25±5.59 31.86±7.52 0.027*Lower Limb 40.9 (30.1–52.3) 44.15 (34.5-54.9) 45.1(25.0-77.3) 0.245Male 45.9(36.4-52.3) 45.80 (34.8-54.9) 46.9(42.4-77.3) 0.376Female 35.78±3.77 39.19±3.6 39.44±6.86 0.203
Note: CKD=Chronic Kidney Disease. *p value <0.05 considered to be significant different among the groups
Table 3 Multiple Linear Regression Analysis with Muscle Mass as the Dependent Variable 
Predictor 
Variables
Male Female 
β 
Value
P Value Confidence Interval 
95.0 %
β Value P Value Confidence Interval 
95.0 %Minimum Maximum Minimum MaximumConstant 3.545 0.000 3.091 3.999 3.723 0.000 3.400 4.046Stage 4vs. 3 0.040 0.565 -0.097 0.176 0.119 0.032* 0.011 0.228Stage 5vs. 3 0.049 0.422 -0.072 0.170 0.119 0.021* 0.019 0.219Age 0.004 0.129 -0.009 0.001 -0.006 0.002* -0.009 -0.002BMI 0.001 0.820 -0.009 0.011 -0.011 0.025* -0.021 -0.002Note: Dependent Variable = Muscle Mass (Whole Body); BMI=Body Mass Index
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hypertension.14After stratifying the data into male and female, the result shows that there is no 
significant difference in whole body’s muscle mass on male subjects; whereas in female 
subjects there is a significant difference in whole body’s muscle mass. No differences in male subjects may occur due to almost all male subjects who have low muscle mass since stage 3 CKD. The difference in whole body’s muscle mass has been shown in female subjects with stage 3 and stage 5 CKD. Statistically, a 
significant difference in muscle mass of female subjects does not correlate with clinical sign due to a high number of female subjects with low muscle mass. Several other factors such as physical activity, nutritional intake, hormonal status, and menopausal status may cause differences in subjects’ muscle mass. This may be due to more daily activities involving the upper and lower extremities. The whole body’s muscle mass may also be affected by low 
muscle mass in the trunk region. A significant difference in muscle mass has also been found in the female’s upper limb area (p=0.027), next to an increase in muscle mass with increasing stage of CKD. This phenomenon has not been clearly explored and need further study. A decrease in muscle mass can occur along 
with a declinein kidney function, as confirmed this study.10 As the CKD stage increases, 
kidney filtration function will decline.1 This condition may cause accumulation of substances that should be excreted through the kidneys. Accumulation of uremic toxins may lead to a variety of clinical symptoms and complications.6,15 Complications that may arise from the accumulation of uremic toxins include the degradation of muscle protein. This may happen due to the increase of ubiquitin and proteasome transcription, resulting in an increase in protein degradation that may cause loss of muscle protein in CKD patients.16,17 Chronic Kidney Disease stage was 
also classified based on kidney ability to filter 
various toxins, the lower the kidney filtration function (higher CKD stage), the higher the amount of toxins that involved in activation of muscle protein degradation process.1,6 Muscle protein degradation was a resultof various mechanisms involving uremic toxins such as metabolic acidosis, insulin/IGF-1 signaling, 
inflammation, decreased hypothalamic function in regulating appetite, and micro RNA deregulation. All of these conditions may lead to the activation of UPS, caspase-3, lysosome and myostatin pathways in muscle 
protein catabolism.16 These conditions may cause an imbalance between protein synthesis and protein degradation, so that there may be a decrease in muscle mass and muscle strength. Loss of appetite may also be caused by a decrease in hypothalamic function. This may also trigger a decrease in muscle mass due to reduced protein intake. Disability, mortality and even mortality may occur as a manifestation of comorbid complications of lowmuscle mass and muscle strength.9This study showed that low muscle mass had been found from stage 3 CKD, however, this study did not measure muscle mass in stage 1 and stage 2 since no clinical signs and symptoms can be observed, even though there is a decrease in GFR.6 Prevention of low muscle mass in CKD patients could be done by among others giving supplementation in the form of essential keto acids and amino acids that are safe for the kidneys to prevent further decline in muscle mass, regulation of nutritional intake with a low protein diet that is appropriate for the needs of each CKD stage,9,18 and examination of muscle mass and body composition and doing routine and controlled physical activity are also recommended to prevent CKD progression even to reduce the risk of death due to loss of muscle mass.9 By preventing a decrease in muscle mass and strength in CKD patients, the progression of CKD canbe prevented. If these things weredone,the risk of heart failure, fractures, infections, muscle weakness, and insulin resistance can also be prevented.9 Furthermore, the high number of CKD patients with low muscle mass suggests that physical activity is needed. We here to recommend exercise in CKD patients as a structured activity that includes aerobic exercise, which uses large amounts of oxygen for example strength training, which involves 
using a large amount of muscle; and flexibility training, which involves joint activity. 19The limitations of this study are unmeasured factors that may affect muscle mass. These factors include data on nutritional intake, hormonal status, menopausal status, and physical activity. Confounding variables in this study are controlled through data analysis 
and data stratification only. Another limitation of this study is that the data cannot be excluded from chronic diseases that may have been preceded CKD. One chronic disease that may become the etiology of CKD is diabetes mellitus. Diabetes mellitus may affect muscle mass variables in the study subjects. Thus, further research is needed by paying attention 
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to and taking into account other factors that can affect muscle mass in CKD patients.To conclude, no difference in the whole body’s muscle mass in male patients with chronic kidney disease stage 3 to stage 5; in opposite, female patients subjects with stage 3 to stage 5 CKD. The low muscle mass found since stage 3CKD indicates that the examination of muscle mass, regulation of protein intake and supplementation of nutrients according to patient’s needsare important. 
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